Novavax, Inc., A Biotechnology Company, Announced That The Us Food And Drug Administration'S (Fda) Vaccines And Related Biological Products Advisory Committee (Vrbpac) Will Review Nvx-Cov2373 Covid-19 Vaccine (Recombinant, Adjuvanted) For Active Immunization Against Sars-Cov-2 At A Meeting Scheduled For June 7, 2022. Vrbpac Reviews And Evaluates Data Regarding The Safety And Efficacy Of Vaccines And Related Biological Products That Are Intended For Use In The Prevention, Treatment, Or Diagnosis Of Human Diseases."We Continue To Hear From Physicians, Healthcare Organizations, And Consumers Who Are Anxiously Awaiting Another Vaccine Option. We Believe Our Vaccine, Built On A Well-Understood Protein-Based Vaccine Platform, Can Play A Part In Fulfilling This Need," Said Stanley C. Erck, President And Chief Executive Officer, Novavax. "We Look Forward To A Productive Vrbpac Meeting And Will Continue To Work With The Fda Throughout The Review Process."Novavax Submitted A Request To The Fda For Emergency Use Authorization (Eua) For Nvx-Cov2373 In January 2022 Based On The Totality Of Pre-Clinical, Clinical, And Manufacturing-Related Data Provided To The Agency.Nvx-Cov2373 Is A Protein-Based Vaccine Engineered From The Genetic Sequence Of The First Strain Of Sars-Cov-2, The Virus That Causes Covid-19 Disease. Nvx-Cov2373 Was Created Using Novavax' Recombinant Nanoparticle Technology To Generate Antigen Derived From The Coronavirus Spike (S) Protein And Is Formulated With Novavax' Patented Saponin-Based Matrix-M Adjuvant To Enhance The Immune Response And Stimulate High Levels Of Neutralizing Antibodies. Nvx-Cov2373 Contains Purified Protein Antigen And Can Neither Replicate, Nor Can It Cause Covid-19.Novavax' Covid-19 Vaccine Is Packaged As A Ready-To-Use Liquid Formulation In A Vial Containing Ten Doses. The Vaccination Regimen Calls For Two 0.5 Ml Doses (5 Mcg Antigen And 50 Mcg Matrix-M Adjuvant) Given Intramuscularly 21 Days Apart. The Vaccine Is Stored At 2
